Join Dr. Guillermo Garcia-Manero in this OncLive Insights program as he delves into the latest advancements in the treatment of myelodysplastic syndrome (MDS), with a specific focus on the emerging role of oral hypomethylating agents (HMAs). This page is funded by Taiho Oncology, Inc. The faculty and publisher are solely responsible for this content. Taiho does not recommend or endorse the use of its products other than as described in the approved labeling. The content of this page is not medical advice and does not replace independent medical judgment.
Join Dr. Guillermo Garcia-Manero in this OncLive Insights program as he delves into the latest advancements in the treatment of myelodysplastic syndrome (MDS), with a specific focus on the emerging role of oral hypomethylating agents (HMAs). In this episode, gain insights about MDS risk stratification and prognosis, and why it is important to treat early.
The role of HMAs in the treatment of patients with intermediate- and high-risk MDS.
Guillermo Garcia-Manero, MD, provides a high-level overview of the effectiveness of oral HMA agents in the treatment of intermediate- and high-risk MDS.
An expert discusses the real-world impact of hypomethylating agents for the treatment of patients with MDS.
A review of the benefits of oral HMA treatments in the management of MDS, and the impact on a patient's quality of life.
An expert discusses data supporting the use of HMAs in the treatment of lower-risk MDS.
An overview of how HMAs are being used to treat CMML and their use in combination with other therapies for patients with AML.
Guillermo Garcia-Manero, MD, reviews potential serious and common adverse effects associated with HMA treatments, shares tips for patient education to help manage these AEs, and discusses if and when a dose reduction or discontinuation may be necessary.
